# Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema

> **NCT04687137** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 12 (actual)

## Conditions studied

- Hereditary Angioedema

## Interventions

- **DRUG:** TAK-743 300 mg

## Key facts

- **NCT ID:** NCT04687137
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-10
- **Primary completion:** 2022-06-18
- **Final completion:** 2022-06-18
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04687137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04687137, "Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04687137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*